Boosting CAR T-cell responses in lymphoma by simultaneous targeting of CD40/4-1BB using oncolytic viral gene therapy
In conclusion, immunostimulatory LOAd703 therapy is an intriguing approach to induce anti-lymphoma immune responses and to improve CAR T-cell therapy in B-cell lymphoma.
Source: Cancer Immunology, Immunotherapy - Category: Cancer & Oncology Source Type: research
More News: Adenoviruses | Allergy & Immunology | Cancer | Cancer & Oncology | Gene Therapy | Genetics | Immunotherapy | Lymphoma